肾素-血管紧张素系统阻断不影响腹主动脉瘤生长、破裂率或择期修复术后围手术期死亡率
该系统综述纳入1项随机对照试验和7项观察性研究共35448例患者,评估ACEI或ARB对腹主动脉瘤生长、破裂及围手术期死亡率的影响。
要点
- 单项研究显示RASB增加择期开放修复术后30天死亡率(OR 5)。
核心结论
- RASB似乎不影响腹主动脉瘤生长和破裂率,但增加择期围手术期死亡率。
- 研究数量少、异质性大且随访有限,不能完全否定RASB作为AAA药物治疗。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,方案注册于PROSPERO(CRD42016054082)。
- 检索Cochrane Central、MEDLINE和Embase至2017年,纳入1项随机对照试验和7项观察性研究,共35448例患者。
主要发现
- 单项充分调整的研究显示RASB增加择期开放AAA修复术后30天死亡率(OR 5,95%CI 1.4-27)。
关键数值与推荐
- 所有研究均调查ACEI,3项研究调查ARB,2项研究包含ACEI或ARB复合RASB组。
- 5项研究评估AAA生长,2项评估破裂率,1项报告择期开放修复术后30天死亡率。
临床怎么用
- 不应以延缓AAA生长或预防破裂为目的常规处方RASB。
- 择期开放AAA修复术前需关注RASB使用与围手术期死亡风险的潜在关联。
局限性
- 纳入研究多为回顾性、异质性大且数量少。
- 长期随访数据有限,无法确定RASB对AAA的远期效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to summarize the literature regarding the effects of renin-angiotensin system blockade (RASB) using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on human abdominal aortic aneurysm (AAA) growth, rupture, and perioperative mortality. METHODS: We conducted a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Our review protocol was registered at the International Prospective Register of Systematic Reviews (CRD42016054082). We searched the Cochrane Central Register of Controlled Trials database, MEDLINE, and Embase from inception to 2017 for studies examining the effects of ACEi or ARB treatment on AAA growth, rupture, or perioperative mortality. Review, abstraction, and quality assessment were conducted in duplicate, and a third author resolved discrepancies. We assessed study quality using the Cochrane and Newcastle-Ottawa scales. We used random-effects models to calculate pooled mean differences and odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quantified using the I2 statistic. RESULTS: Our search yielded 525 articles. One randomized and seven observational studies involving 35,448 patients were included. Inter-rater agreement was excellent (κ = 0.78), and risk of bias was low to moderate. All studies investigated ACEis, three studies investigated ARBs, and two studies included a composite RASB group consisting of ACEi or ARB users. Five studies assessed AAA growth, two assessed rupture rate, and one reported 30-day mortality after elective open repair. There was no difference in AAA growth rate between RASB and control (mean difference, 0.03 mm/y; 95% CI, -0.40 to 0.46; P = .88; I2 = 60%). No protective effect of RASB (OR, 0.92; 95% CI, 0.72, 1.16; P = .47; I2 = 90%) was demonstrated for AAA rupture. Finally, RASB increased 30-day mortality in patients undergoing elective open AAA repair (OR, 5; 95% CI, 1.4, 27) according to a single well-adjusted study. CONCLUSIONS: RASB does not appear to affect AAA growth and rupture rate but increases elective perioperative mortality. The small number of heterogeneous, retrospective studies and limited long-term follow-up preclude a definitive dismissal of RASB as pharmacotherapy for AAA. Prospective, long-term data are needed to clarify the effect of RASB on AAA growth, rupture, and perioperative mortality.
引用
- Salata K, Syed M, Hussain MA, et al. Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair. J Vasc Surg. 2017. PMID: 29175038. doi:10.1016/j.jvs.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。